Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PHGDH | O43175 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1507253 | 0.94 | HRH3 (0.52) | POLBHSD17B10KDM4EALDH1A1L3MBTL3 | |
| SCHEMBL18619500 | 0.94 | POLB (0.59) | POLBHSD17B10KDM4EALDH1A1L3MBTL3 | |
| SCHEMBL3601428 | 0.94 | POLB (0.59) | POLBHSD17B10KDM4EALDH1A1L3MBTL3 | |
| SCHEMBL3768409 | 0.92 | POLB (0.56) | POLBHSD17B10KDM4EALDH1A1L3MBTL3 | |
| SCHEMBL65252 | 0.88 | POLB (0.52) | POLBHSD17B10KDM4EALDH1A1L3MBTL3 | |
| SCHEMBL3592203 | 0.84 | HRH3 (0.58) | KDM4EALDH1A1L3MBTL3L3MBTL1HRH3 | |
| SCHEMBL4471423 | 0.84 | L3MBTL3 (0.57) | POLBHSD17B10ALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL4334091 | 0.84 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1MEN1KMT2A | |
| SCHEMBL65329 | 0.83 | HRH3 (0.47) | POLBHSD17B10KDM4EALDH1A1L3MBTL3 | |
| SCHEMBL18125956 | 0.83 | CHRM1 (0.50) | POLBHSD17B10KDM4EALDH1A1L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333400-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-30 | — | — | US | disclosed |
| US-20240368140-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-11-07 | — | — | US | disclosed |
| WO-2019199667-A2 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | KEANEY GREGG F (US) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368140-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | PLAAT5, PLAAT3, PLAAT4 | POLB 1222/4885HSD17B10 854/4885KDM4E 2775/4885 |
| US-20250333400-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | SNRPE, SNRPB2, DDX21 | POLB 1292/4885HSD17B10 738/4885KDM4E 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.